Is Excitement Over Eli Lilly’s Alzheimer’s Drug Overdone?
June 12, 2015 at 11:23 AM EDT
Has Eli Lilly & Co. (LLY) run its race? After running up in pre-market action, the U.S. drug giant is pulling back in regular market action, falling 2.4% to $84.23 after an analyst cautioned investor that it’s too soon to draw any conclusions about an experimental Alzheimer’s treatment. Lilly has enjoyed a recent surge, hitting [...]
